Arrowhead Pharmaceuticals (ARWR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$86.34-0.17%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — EPS loss narrows from current levels: EPS -1.36 vs target >-0.80.
Arrowhead Pharmaceuticals beat EPS estimates by 16% in Q2 FY2026 with EPS of -$0.93. The company aims to strengthen commercial presence for REDEMPLO despite revenue falling to $73.7M in Q2 2026. Recent positive hires and stable management support recovery. The stock gained 42% in 63 days, showing market optimism.
Revenue dropped sharply from $542.7M in 2025-Q2 to $73.7M in 2026-Q2, signaling weak commercial execution. The company remains loss-making with negative EPS and no clear revenue growth guidance. Analysts expect revenue to decline about 39% next year, reflecting ongoing challenges.
The price is about 23% above our fair value near $70 and 22% below the Street median target of $90. Analysts expect a 39% revenue decline next year, which is priced in, but our fair value is more conservative than the Street's optimistic range.
Breaks if: quarterly REDEMPLO revenue falls below $70M next 4 quarters
Continue building momentum and market penetration for REDEMPLO in the U.S. and expand regulatory approvals internationally.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state is cautious, as the company is navigating both positive and negative factors impacting its performance.
The market appears to be pricing in a durable premium compared to peers, indicating expectations for future growth. However, there is an expectations gap, suggesting that current performance may not fully justify this premium.
Management has made progress in advancing its RNAi therapeutic pipeline and strengthening its financial position. However, the company remains loss-making, and recent financial performance has not kept pace with its industry peers, which could pose challenges.
The long-term thesis hinges on the performance of sector bellwethers and the company's ability to execute on its strategic priorities. Additionally, macroeconomic factors, such as job reports and recession fears, could significantly impact the company's trajectory.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company advanced its RNAi therapeutic pipeline, which strengthens the outlook. However, it also reported a significant earnings miss, which weakens the read.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 of last 3 quarters. REDEMPLO prescriptions grew from over 100 in 2025-Q4 to more than 400 by 2026-Q1, with prescription volume roughly doubling in 2026-Q2. The company secured marketing authorizations in Europe and Australia and established favorable U.S. payer policies. The trajectory shows delivering commercial growth and expanding market access.
“REDEMPLO prescription volume roughly doubled during the fiscal third quarter; favorable policies in place for significant U.S. payers.”
“REDEMPLO launch continued to build momentum; total prescriptions exceed 400; new weekly prescriptions averaging 30 per week.”
“U.S. FDA approved REDEMPLO; launched independently in U.S.; over 100 prescriptions received to date.”
Breaks if: EPS loss worsens beyond -$1.0 next 4 quarters
Breaks if: Major management departures or negative leadership news
Over the next 1 to 3 years, ARWR's performance will depend on its execution and external market conditions. Not investment advice.